Form 4: Cadrenal CFO Sells Shares Under 10b5-1 Plan

Cadrenal Therapeutics' Chief Financial Officer, Matthew K. Szot, sold 107 shares of common stock for $13.99 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported a sale of common stock.
• The transaction involved the disposition of 107 shares of Cadrenal Therapeutics common stock.
• The shares were sold at a price of $13.99 per share.
• The sale occurred on October 6, 2025.
• This transaction was conducted in accordance with a Rule 10b5-1 trading arrangement, indicating a pre-planned sale.
• Following this transaction, Matthew K. Szot directly beneficially owns 17,026 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be perceived negatively, the small number of shares (107) and the explicit mention of a Rule 10b5-1 trading arrangement indicate a pre-planned, routine transaction rather than a reaction to new information, thus mitigating any negative implications.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors, though the small volume and 10b5-1 plan mitigate this.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transaction represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement.

Industry Context

Insider transactions, particularly sales, are common occurrences in publicly traded companies. Sales executed under a Rule 10b5-1 plan are pre-scheduled and generally viewed as less indicative of management's immediate sentiment about the company's prospects compared to unscheduled sales, as they are designed to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by a CFO under a 10b5-1 plan is unlikely to have a significant direct impact on existing shareholders, as it is a routine, pre-scheduled transaction.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned insider sale of a very small number of shares by the CFO under a Rule 10b5-1 trading arrangement. Such a transaction typically does not reflect a change in the company's fundamental outlook or warrant a shift in investment recommendation. Investors should continue to evaluate Cadrenal Therapeutics based on its core business performance, financial results, and strategic initiatives rather than this minor, scheduled insider transaction.

Keywords

Cadrenal Therapeutics, CVKD, Matthew K. Szot, Chief Financial Officer, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Transaction